Literature DB >> 31931272

The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.

Simon B Goldberg1, Brian T Pace2, Christopher R Nicholas3, Charles L Raison4, Paul R Hutson5.   

Abstract

The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled; N = 117), within-group pre-post and pre-follow-up effects on anxiety and depression were large (Hedges' gs=1.16 to 1.47) and statistically significant. Across three placebo-controlled studies, pre-post placebo-controlled effects were also large (gs = 0.82 to 0.83) and statistically significant. No serious adverse events were reported. Limitations include the small number of studies and risk for bias within studies. Results tentatively support future research on psilocybin for the treatment of anxiety and depression.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety; Depression; Psilocybin

Year:  2020        PMID: 31931272     DOI: 10.1016/j.psychres.2020.112749

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  18 in total

1.  Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.

Authors:  Danilo De Gregorio; Argel Aguilar-Valles; Katrin H Preller; Boris Dov Heifets; Meghan Hibicke; Jennifer Mitchell; Gabriella Gobbi
Journal:  J Neurosci       Date:  2020-11-30       Impact factor: 6.167

Review 2.  Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Authors:  Susan Ling; Felicia Ceban; Leanna M W Lui; Yena Lee; Kayla M Teopiz; Nelson B Rodrigues; Orly Lipsitz; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Kangguang Lin; Roger Ho; Joshua D Rosenblat; David Castle; Roger S McIntyre
Journal:  CNS Drugs       Date:  2021-11-17       Impact factor: 5.749

3.  Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.

Authors:  Elena Argento; M Eugenia Socias; Kanna Hayashi; JinCheol Choi; Lindsay Mackay; Devon Christie; M-J Milloy; Kora DeBeck
Journal:  Int J Drug Policy       Date:  2021-11-07

4.  Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity.

Authors:  Anat Levit Kaplan; Danielle N Confair; Kuglae Kim; Ximena Barros-Álvarez; Ramona M Rodriguiz; Ying Yang; Oh Sang Kweon; Tao Che; John D McCorvy; David N Kamber; James P Phelan; Luan Carvalho Martins; Vladimir M Pogorelov; Jeffrey F DiBerto; Samuel T Slocum; Xi-Ping Huang; Jain Manish Kumar; Michael J Robertson; Ouliana Panova; Alpay B Seven; Autumn Q Wetsel; William C Wetsel; John J Irwin; Georgios Skiniotis; Brian K Shoichet; Bryan L Roth; Jonathan A Ellman
Journal:  Nature       Date:  2022-09-28       Impact factor: 69.504

5.  Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice.

Authors:  Carine Bécamel; Dimitri De Bundel; Błażej D Pędzich; Sarah Rubens; Mehdi Sekssaoui; Anouk Pierre; Andries Van Schuerbeek; Philippe Marin; Joel Bockaert; Emmanuel Valjent
Journal:  Neuropsychopharmacology       Date:  2022-04-21       Impact factor: 8.294

6.  Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.

Authors:  Brian T Anderson; Alicia Danforth; Prof Robert Daroff; Christopher Stauffer; Eve Ekman; Gabrielle Agin-Liebes; Alexander Trope; Matthew Tyler Boden; Prof James Dilley; Jennifer Mitchell; Joshua Woolley
Journal:  EClinicalMedicine       Date:  2020-09-24

7.  Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.

Authors:  Simon B Goldberg; Benjamin Shechet; Christopher R Nicholas; Chi Wing Ng; Geetanjali Deole; Zhuofan Chen; Charles L Raison
Journal:  Psychol Med       Date:  2020-11-04       Impact factor: 7.723

8.  Associations between lifetime classic psychedelic use and markers of physical health.

Authors:  Otto Simonsson; James D Sexton; Peter S Hendricks
Journal:  J Psychopharmacol       Date:  2021-03-09       Impact factor: 4.153

Review 9.  New agents and perspectives in the pharmacological treatment of major depressive disorder.

Authors:  Marsal Sanches; Joao Quevedo; Jair C Soares
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-11-05       Impact factor: 5.067

10.  Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles.

Authors:  Ekaterina V Fedorova; Carolyn F Wong; Janna Ataiants; Ellen Iverson; Bridgid M Conn; Stephen E Lankenau
Journal:  Drug Alcohol Depend       Date:  2021-02-22       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.